See more : Erie Indemnity Company (ERIE) Income Statement Analysis – Financial Results
Complete financial analysis of Stealth BioTherapeutics Corp (MITO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Stealth BioTherapeutics Corp, a leading company in the Biotechnology industry within the Healthcare sector.
- Bancorp. of Southern Indiana (BCSO) Income Statement Analysis – Financial Results
- Hangzhou Hota M&E Holdings Co., Ltd. (001225.SZ) Income Statement Analysis – Financial Results
- Entera Bio Ltd. WT EXP 062723 (ENTXW) Income Statement Analysis – Financial Results
- Air France-KLM SA (AFLYY) Income Statement Analysis – Financial Results
- Norwood Financial Corp. (NWFL) Income Statement Analysis – Financial Results
Stealth BioTherapeutics Corp (MITO)
About Stealth BioTherapeutics Corp
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 21.09M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 21.09M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.56M | 29.31M | 44.60M | 53.06M | 63.22M | 48.45M |
| General & Administrative | 19.75M | 19.37M | 22.32M | 22.22M | 16.50M | 13.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.75M | 19.37M | 22.32M | 22.22M | 16.50M | 13.40M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 46.30M | 48.67M | 66.92M | 75.28M | 79.72M | 61.85M |
| Cost & Expenses | 46.30M | 48.67M | 66.92M | 75.28M | 79.72M | 61.85M |
| Interest Income | 3.00K | 139.00K | 988.00K | 195.09K | 56.84K | 799.02K |
| Interest Expense | 1.24M | 1.81M | 6.67M | 21.36M | 3.28M | 0.00 |
| Depreciation & Amortization | 77.00K | 232.00K | 284.00K | 309.04K | 346.87K | 312.54K |
| EBITDA | -51.21M | -55.42M | -64.78M | -75.05M | -79.28M | -60.74M |
| EBITDA Ratio | 0.00% | 0.00% | -307.19% | 0.00% | 0.00% | 0.00% |
| Operating Income | -51.29M | -48.67M | -45.83M | -75.28M | -79.72M | -61.85M |
| Operating Income Ratio | 0.00% | 0.00% | -217.35% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.22M | -8.79M | -25.90M | -21.43M | -3.19M | 799.02K |
| Income Before Tax | -52.53M | -57.46M | -71.73M | -96.71M | -82.91M | -61.05M |
| Income Before Tax Ratio | 0.00% | 0.00% | -340.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.24M | -6.98M | -19.23M | -76.21K | 92.30K | 799.02K |
| Net Income | -53.77M | -57.46M | -71.73M | -96.71M | -82.91M | -61.05M |
| Net Income Ratio | 0.00% | 0.00% | -340.15% | 0.00% | 0.00% | 0.00% |
| EPS | -1.16 | -1.24 | -2.29 | -2.93 | -5.22 | -2.99 |
| EPS Diluted | -1.16 | -1.24 | -2.29 | -2.93 | -5.22 | -2.99 |
| Weighted Avg Shares Out | 46.35M | 46.35M | 31.31M | 33.02M | 15.88M | 20.38M |
| Weighted Avg Shares Out (Dil) | 46.35M | 46.35M | 31.31M | 33.02M | 15.88M | 20.38M |
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
Zacks Investment Research Lowers Stealth BioTherapeutics (NASDAQ:MITO) to Hold
Stealth BioTherapeutics Corp (NASDAQ:MITO) Given Consensus Rating of "Buy" by Brokerages
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
Stealth BioTherapeutics (NASDAQ:MITO) Rating Reiterated by Cantor Fitzgerald
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data
Source: https://incomestatements.info
Category: Stock Reports